2026 Q2 - tulosraportti
30 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 262 | - | - | ||
| 38 | - | - | ||
| 2 | - | - | ||
| 400 | - | - | ||
| 603 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenSwiss Nordic Bio – some interesting signals Read BioStock's report from Swiss Nordic Bio in Zurich, where Circio among others participated. What I found most interesting was actually not a specific piece of news, but what Erik Wiklund says about what Circio wants to achieve in the capital market. He says they want to strengthen the shareholder base with international specialist and institutional investors, and highlights that liquidity is important to be able to attract larger investments. That also makes some sense in light of the latest private placement of approx. 200 MNOK, where international investors specifically came in. Another point from the conference that I think is relevant for Circio, is that pharma to a greater extent seems to be willing to enter earlier into biotech projects. One does not necessarily need to wait for clinical results if preclinical data are strong enough and a clear development candidate has been reached. That fits quite well with where Circio is now. They have already shown significant expression advantage with circVec in several tissues, the CNS program with a large global pharma company has moved on to in vivo testing, and at the same time the new capital is being used to find and secure delivery technology around in vivo CAR-T. That of course does not mean that a licensing agreement or an acquisition is just around the corner. There is still a lot that needs to be documented. But if the upcoming data packages show that circVec not only gives higher expression, but actually provides a relevant therapeutic advantage in disease models and eventually a clear development candidate, the threshold for commercial interest might be lower than many perhaps assume. For me, this is therefore mostly an interesting data point around Circio's strategy – not a piece of news that changes the case overnight. However, it will be increasingly interesting to see what they actually manage to document through the rest of 2026 and into 2027. https://biostock.se/2026/10/report-from-swiss-nordic-bio-what-it-takes-for-nordic-biotech-to-attract-capital/
·4 t sittenOpt out of securities lending for shorting
It must be terribly boring for those who bought Emiaksjer at 11,80 😅 or maybe they are fooling the market by saying that the shares were sold at 11,80 but maybe they got them for a tenner or less?? Nothing surprises me when it comes to Norway anymore. Know that there will be a lot of whining and jabbering about this now but what if it is right...?!? There are many sneaks and corrupt people in Norway even though we like to pretend that everything is right and legitimate. Abroad we have a different reputation.
·6 t sittenHoly what a purchase
·6 t sittenshort attack!Traders are running the same strategy - selling down to a large block that swallows everything up low again. Circio is the golden calf, and where traders can make money, they use days with low volume on so-called "false flag operations"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
30 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenSwiss Nordic Bio – some interesting signals Read BioStock's report from Swiss Nordic Bio in Zurich, where Circio among others participated. What I found most interesting was actually not a specific piece of news, but what Erik Wiklund says about what Circio wants to achieve in the capital market. He says they want to strengthen the shareholder base with international specialist and institutional investors, and highlights that liquidity is important to be able to attract larger investments. That also makes some sense in light of the latest private placement of approx. 200 MNOK, where international investors specifically came in. Another point from the conference that I think is relevant for Circio, is that pharma to a greater extent seems to be willing to enter earlier into biotech projects. One does not necessarily need to wait for clinical results if preclinical data are strong enough and a clear development candidate has been reached. That fits quite well with where Circio is now. They have already shown significant expression advantage with circVec in several tissues, the CNS program with a large global pharma company has moved on to in vivo testing, and at the same time the new capital is being used to find and secure delivery technology around in vivo CAR-T. That of course does not mean that a licensing agreement or an acquisition is just around the corner. There is still a lot that needs to be documented. But if the upcoming data packages show that circVec not only gives higher expression, but actually provides a relevant therapeutic advantage in disease models and eventually a clear development candidate, the threshold for commercial interest might be lower than many perhaps assume. For me, this is therefore mostly an interesting data point around Circio's strategy – not a piece of news that changes the case overnight. However, it will be increasingly interesting to see what they actually manage to document through the rest of 2026 and into 2027. https://biostock.se/2026/10/report-from-swiss-nordic-bio-what-it-takes-for-nordic-biotech-to-attract-capital/
- ·4 t sittenOpt out of securities lending for shortingIt must be terribly boring for those who bought Emiaksjer at 11,80 😅 or maybe they are fooling the market by saying that the shares were sold at 11,80 but maybe they got them for a tenner or less?? Nothing surprises me when it comes to Norway anymore. Know that there will be a lot of whining and jabbering about this now but what if it is right...?!? There are many sneaks and corrupt people in Norway even though we like to pretend that everything is right and legitimate. Abroad we have a different reputation.
- ·6 t sittenHoly what a purchase
- ·6 t sittenshort attack!Traders are running the same strategy - selling down to a large block that swallows everything up low again. Circio is the golden calf, and where traders can make money, they use days with low volume on so-called "false flag operations"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 262 | - | - | ||
| 38 | - | - | ||
| 2 | - | - | ||
| 400 | - | - | ||
| 603 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
30 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenSwiss Nordic Bio – some interesting signals Read BioStock's report from Swiss Nordic Bio in Zurich, where Circio among others participated. What I found most interesting was actually not a specific piece of news, but what Erik Wiklund says about what Circio wants to achieve in the capital market. He says they want to strengthen the shareholder base with international specialist and institutional investors, and highlights that liquidity is important to be able to attract larger investments. That also makes some sense in light of the latest private placement of approx. 200 MNOK, where international investors specifically came in. Another point from the conference that I think is relevant for Circio, is that pharma to a greater extent seems to be willing to enter earlier into biotech projects. One does not necessarily need to wait for clinical results if preclinical data are strong enough and a clear development candidate has been reached. That fits quite well with where Circio is now. They have already shown significant expression advantage with circVec in several tissues, the CNS program with a large global pharma company has moved on to in vivo testing, and at the same time the new capital is being used to find and secure delivery technology around in vivo CAR-T. That of course does not mean that a licensing agreement or an acquisition is just around the corner. There is still a lot that needs to be documented. But if the upcoming data packages show that circVec not only gives higher expression, but actually provides a relevant therapeutic advantage in disease models and eventually a clear development candidate, the threshold for commercial interest might be lower than many perhaps assume. For me, this is therefore mostly an interesting data point around Circio's strategy – not a piece of news that changes the case overnight. However, it will be increasingly interesting to see what they actually manage to document through the rest of 2026 and into 2027. https://biostock.se/2026/10/report-from-swiss-nordic-bio-what-it-takes-for-nordic-biotech-to-attract-capital/
- ·4 t sittenOpt out of securities lending for shortingIt must be terribly boring for those who bought Emiaksjer at 11,80 😅 or maybe they are fooling the market by saying that the shares were sold at 11,80 but maybe they got them for a tenner or less?? Nothing surprises me when it comes to Norway anymore. Know that there will be a lot of whining and jabbering about this now but what if it is right...?!? There are many sneaks and corrupt people in Norway even though we like to pretend that everything is right and legitimate. Abroad we have a different reputation.
- ·6 t sittenHoly what a purchase
- ·6 t sittenshort attack!Traders are running the same strategy - selling down to a large block that swallows everything up low again. Circio is the golden calf, and where traders can make money, they use days with low volume on so-called "false flag operations"
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 262 | - | - | ||
| 38 | - | - | ||
| 2 | - | - | ||
| 400 | - | - | ||
| 603 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt